Pipeline
Our pipeline
Our soluble TCR-based therapies hold the potential to transform the lives of people living with cancer and a wide spectrum of immune-mediated diseases. Leveraging our platform technologies, we are rapidly advancing a robust and differentiated pipeline of specificity- and affinity-enhanced soluble TCR engagers for accelerated clinical impact.
Our lead asset
ENGI-004
ENGI-004 is an inhibitory specTR (inspecTR) that targets an MHC-related receptor overexpressed at barrier sites of the human body, such as the skin and the gut. ENGI-004 is being developed to treat inflammatory conditions affecting these tissues, including atopic dermatitis (eczema) and ulcerative colitis.
By specifically targeting inflamed tissues, ENGI-004 is designed to deliver potent inhibitory signals at the relevant site for enhanced efficacy and safety. We are deploying our advanced AI-guided protein engineering platforms to rapidly progress ENGI-004 through its discovery stage and expect to enter clinical studies in 2028.